Genmab/$GMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Ticker
$GMAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Copenhagen, Denmark
Employees
2,638
ISIN
US3723032062
Website
Genmab Metrics
BasicAdvanced
$13B
1.12
$18.36
0.82
-
Price and volume
Market cap
$13B
Beta
0.82
52-week high
$28.56
52-week low
$17.24
Average daily volume
1.5M
Financial strength
Current ratio
5.34
Quick ratio
5.324
Long term debt to equity
2.436
Total debt to equity
2.7
Interest coverage (TTM)
59.70%
Profitability
EBITDA (TTM)
1,144.737
Gross margin (TTM)
95.12%
Net profit margin (TTM)
35.27%
Operating margin (TTM)
33.97%
Effective tax rate (TTM)
13.85%
Revenue per employee (TTM)
$1,220,000
Management effectiveness
Return on assets (TTM)
11.54%
Return on equity (TTM)
22.80%
Valuation
Price to earnings (TTM)
1.118
Price to revenue (TTM)
0.394
Price to book
15.73
Price to tangible book (TTM)
26.16
Price to free cash flow (TTM)
1.132
Free cash flow yield (TTM)
88.31%
Free cash flow per share (TTM)
1,812.14%
Growth
Revenue change (TTM)
25.43%
Earnings per share change (TTM)
276.80%
3-year revenue growth (CAGR)
35.22%
10-year revenue growth (CAGR)
41.16%
3-year earnings per share growth (CAGR)
52.13%
10-year earnings per share growth (CAGR)
33.18%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Bulls say / Bears say
Genmab's revenue increased by 31% in 2024, primarily driven by higher royalties from DARZALEX and Kesimpta, indicating strong product performance and market demand. (tradingview.com)
The acquisition of ProfoundBio for $1.8 billion provides Genmab with worldwide rights to three clinical-stage candidates, potentially expanding its oncology portfolio and future revenue streams. (reuters.com)
EPKINLY achieved $281 million in sales in 2024, with projections to surpass $3 billion in peak sales, reflecting strong adoption and growth potential in the oncology market. (finviz.com)
Truist Securities reduced Genmab's stock price target to $45 from $50, following Johnson & Johnson's decision not to continue with the development of GEN3014, indicating potential challenges in pipeline development. (investing.com)
Morgan Stanley assigned an 'Equalweight' rating with a $31 price target, citing uncertainties surrounding pipeline decisions and recent development setbacks, which may impact investor confidence. (investing.com)
JPMorgan downgraded Genmab's stock from 'Overweight' to 'Neutral,' highlighting a potential 15% to 22% downside to consensus 2025 and 2026 EBIT forecasts due to increased operational expenditures. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Genmab News
AllArticlesVideos
Transactions in Connection with Share Buy-back Program
GlobeNewsWire·4 days ago
Capital Increase in Genmab as a Result of Employee Warrant Exercise
GlobeNewsWire·1 week ago
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $13B as of June 27, 2025.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 1.12 as of June 27, 2025.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.82. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.